



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : A61K 9/127, 47/48, 39/44, 51/12	A1	(11) International Publication Number: <b>WO 99/29302</b>
		(43) International Publication Date: 17 June 1999 (17.06.99)

(21) International Application Number: PCT/SE98/02231  
 (22) International Filing Date: 4 December 1998 (04.12.98)  
 (30) Priority Data:  
 9704549-6 5 December 1997 (05.12.97) SE


(71)(72) Applicants and Inventors: EDWARDS, Katarina [SE/SE]; Björkgatan 5 K, S-753 28 Uppsala (SE). CARLSSON, Jörgen [SE/SE]; Karlsrogatan 50, S-752 39 Uppsala (SE). SJÖBERG, Stefan [SE/SE]; Sibyllegatan 7, S-752 31 Uppsala (SE).

(74) Agents: ALDENBÄCK, Ulla et al.; Dr. Ludwig Brann Patentbyrå AB, P.O. Box 1344, S-751 43 Uppsala (SE).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published  
 With international search report.  
 With amended claims.

(54) Title: DRUG DELIVERY SYSTEM WITH TWO-STEP TARGETING



(57) Abstract

The present invention relates to a drug delivery system with two-step targeting, which comprises a combination: (a) a lipid carrier provided with cell targeting agent(s) to target the drug delivery system to specific cells or tissues; and (b) a drug enclosed in said lipid carrier and provided with a DNA targeting agent to target the drug to the nuclei of specific target cells. Furthermore, the invention relates to a method of cancer therapy in which the above drug delivery system is administered to a cancer patient. The goal is to treat or analyse both large tumour masses as well as small tumour cell clusters and single spread tumour cells. According to the invention, drug uptake in tumours will be markedly increased at the same time as the interaction of the drug with healthy organs and tissues can be minimized. The invention gives potential to convert palliative into curative treatment.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**Background of the invention**

In order to increase the efficiency of tumour therapy, the possibilities of using tumour seeking molecules that deliver the toxic agent specifically to the tumour cells are being explored. Radionuclides have recently been applied for cell targeted radiotherapy of malignant lymphomas (Press, 1995) and curative treatments have been achieved in some cases. So far, this is the only known case when therapy, based on macromolecular targeting agents, has been successfully applied. The reasons for the good results are probably a combination of two fortunate circumstances. The lymphoma cells are unusually easy to find for the targeting agent due to the cells main localisation in the systemic circulation. Furthermore, lymphoma cells are among the most radiation sensitive human cells presently known.

In other diseases like melanomas, gliomas and a variety of adenocarcinomas (e.g. prostate, breast and colon tumours) it has not been possible to give curative treatments with targeted radionuclides yet. The limitations appear to be partly due to that the first step in the targeting process (to find the tumour cells) is not efficient enough. A further difficulty is that, when the targeting agent anyhow has succeeded to reach the tumour cells, the energy delivery (the ionisation energy) does not damage the cell enough. The low energy delivery is due to both the limited number of nuclides reaching the cell and the fact that the radioactivity to a large extent is located in the cellular membrane or in the cytoplasm. Such a cellular localisation means that far from all emitted radiation quanta passes through the nuclear DNA. This is very unfortunate since the nuclear DNA is the critical target in the cell and severe damage to DNA is necessary to stop the proliferation of the cell.

Localization in the cell nucleus may be accomplished by linking the nuclides to substances with high affinity for DNA. These nuclide-carrying substances may

<b>CONFIRMATION COPY</b>
------------------------------

be DNA-intercalators such as phenanthridinium, acridine and naphthalimide derivatives (Sjöberg et al 1997, Ghaneolhosseini et al 1997) or compounds which interact electrostatically with DNA such as spermine, spermidine, and putrecine derivatives (Sjöberg 1997).

Liposomes have for a long time been interesting as potential drug carriers. The unique structure allows transport of both fat soluble and water soluble substances. Furthermore, the endothelium of tumours is more permeable than normal endothelium and a spontaneous accumulation in tumour tissue can be achieved. To increase circulation time and increase the stability of the liposomes it is important to select a proper lipid composition in the liposome membrane. The destabilization of the liposomes can be further minimized when the surface of the liposome is provided with polymers. Several types of polymers give increased circulation time but polyethyleneglycol (PEG) has so far given the best result (Lasic and Martin 1995).

When the liposome, filled with a toxic substance, has reached the target cell the content of the liposome must be emptied. This occurs naturally by passive leakage and the permeability of the liposome membrane can also be modified by varying the composition of the lipids. The uptake by passive diffusion is not very efficient, most of the liposome content is lost already before it reaches the cell membrane. Furthermore, depending on the properties of the drug, such as fat solubility and charge, a substantial part can be trapped in the cell membrane.

A way of increasing the uptake and simultaneously avoid membrane localization, is to utilize ligands, antibodies and antibody fragments or other suitable agents, with high specificity for receptors or other target structures with endocytotoxic ability. Internalization of whole liposomes into cells has been shown in in vitro experiments where folic acid, or a Fab' fragment directed against glycoprotein p185<sup>HER2</sup> was conjugated to stabilized liposomes (Kirpotin et al. 1997, Lee and Low 1994, Park et al. 1995). When the liposome has been

internalized into the cell the enclosed substance can either diffuse through the liposome and endosome membranes into the cytoplasm or, in some cases, be released after lysozymal degradation of the carrier liposome. However, the problem of directing drugs to the nucleus of specific target cells still has to be solved.

### **Summary of the invention**

The present invention solves the problem of directing drugs to the nucleus of specific target cells. By providing a new two-step targeting system for drug delivery, the invention provides for efficient delivery of different drugs to the nuclei of tumour cells. This means that the toxicity for normal organs is minimized. A further advantage is that the invention enables administration of therapeutic doses also to spread tumour cells and metastases. The purpose of the invention, is to treat or analyse both large tumour masses as well as small tumour cell clusters and single spread tumour cells.

According to the invention, large amounts of nuclides are delivered to the tumour cells and these nuclides will reach and bind to the nuclear DNA. The latter means that each radioactive decay will damage nuclear DNA and thereby the therapeutical process will be more efficient. In fact, the same amount of radioactive nuclides will impose at least ten times higher damage when the radioactivity is localised in the nuclear DNA than when localised outside the cell nucleus. The same arguments are valid when stable nuclides for neutron or photon activation are applied. The former characteristic of the invention, i.e. the delivery of large amounts of nuclides to the tumour cells, may for radioactive nuclides mean the difference between palliative and curative treatment. If conventional targeting processes with one step targeting are applied only palliative treatments appear possible.

Thus, in a first aspect the invention relates to a drug delivery system with two-step targeting, which comprises a combination of:

- a) a lipid carrier provided with cell targeting agent(s) to target the drug delivery system to specific cells or tissue; and
- b) drug(s) enclosed in said lipid carrier and provided with a DNA targeting agent to target the drug to the nuclei of specific target cells.

The ratio between a) and b) may vary between 1 to  $10^{-8}$ , depending on the selected drug. The possibility of enclosing a high number of drugs in a lipid carrier means that the therapeutical efficiency will increase dramatically compared to known tumour drugs.

Preferably, the drugs are nuclides which either can be radioactive or stable or other DNA damaging substances, such as PNA and DNA alkylating agents. The drugs can be used either for therapeutic or diagnostic purposes. For nuclides, the above ratio between a) and b) is preferably in the lower range. For other DNA damaging substances, a smaller drug amount will suffice.

The lipid carrier can be any lipid aggregate with ability to enclose a drug and the preferred lipid carrier is a liposome, but a cubosome, hexosome or micelle may be equally or more potent for certain applications.

The cell targeting agent associated with the liposomal surface is selected from the group consisting of natural or synthetic ligands, antibodies, antibody fragments or other biomolecules suitable for the purpose.

According to the invention, different types of toxic loads, such as nuclides, can be used. Nuclides such as  $^{125}\text{I}$  (Auger radiation) and  $^{211}\text{At}$  ( $\alpha$ -particles) provide high local ionization density and damage DNA very efficiently. These short range radiators require a targeting part which enables internalizing of the liposomes.

Among stable nuclides, boron ( $^{10}\text{B}$ ) and gadolinium ( $^{157}\text{Gd}$ ) are preferred types of cancer agents. After administration of the liposomes, the tumour area is, in this

case, irradiated by neutrons. Hereby, not stable  $^{11}\text{B}$  is formed from  $^{10}\text{B}$  and it rapidly disintegrates and gives particle radiation in the form of He ( $\alpha$  particles) and Li nuclei, which effectively will kill the targeted cell (Carlsson et al. 1994). Other reactions take place after  $^{157}\text{Gd}$  captures a neutron. Stable nuclides suitable for photon activation (e.g. iodine and bromine) can also be considered. As for substances with short range radiation, the stable nuclide containing substance is to be located in the nucleus and most preferably bind to the nuclear DNA of the tumour cell.

Long range  $\beta$ -radiators, such as  $^{131}\text{I}$ , can be used as a complement. Such nuclides provide therapeutic action is even if the radionuclide only binds to the cytoplasm or the membrane of the cell. These types of  $\beta$ -radiators can be used to obtain cross-fire radiation in larger cell groupings.

The DNA targeting substance coupled directly to the nuclides can be a DNA-intercalator and/or a compound that interacts electrostatically or reacts chemically with DNA.

In a second aspect, the invention relates to a method for cancer therapy, comprising administering to a subject in need thereof a therapeutically efficient amount of the drug delivery system according to the invention. If the drug delivery system comprises a nuclide to be activated, the method also comprises the further step of irradiating the cancer area.

Thus, the invention relates to stabilized liposomes with double targeting, SLT-particles, for transport of a toxic substance to the cell nucleus. By enclosing the toxic substance in SLT-particles the uptake in tumours will be markedly increased at the same time as the interaction of the substance with healthy organs and tissues can be minimized. An appropriately selected targeting ligand allows administration of a toxic substance in therapeutic doses also to spread tumour cells.

### **Detailed description of the invention**

The invention will now be described more closely in relation to the accompanying drawings and the example.

Figure 1 shows an SLT-particle filled with a toxic substance; and Figure 2 shows SLT-particles (1) binding to receptors (2) on the surface of the target cell and being internalized by endocytosis (3). The toxic load is released (4) and can diffuse into the cytoplasm.

### **EXAMPLE: Preparation of SLT-particles with different properties**

#### **a. The lipid carrier**

The structure of the SLT-particles, their stability and leakage are mostly determined by the properties of the liposome part. The composition in the lipid membrane, as well as concentration and type of PEG-polymer, is adjusted according to the toxic load and the targeting agents which are used.

The size of the liposomes is adjusted to ensure optimum accumulation in the target tissue, target cells and/or target site. Cryo-transmission electromicroscopy, light scattering, NMR and different photophysical methods are used for the analyses of the liposome structure and size. A preferred size range of the liposomes is 50-150 nm.

Properly designed liposomes have the potential to carry large amounts of, in particular, water soluble substances. In order to optimize the amount of substance enclosed in the aqueous core of the liposome, the use of active loading techniques is often necessary. Effective loading techniques based on pH gradients are preferably used in the invention.

In summary, the lipid carrier must have the following properties:

- be stable against extracellular leakage of the entrapped drug



- have qualities which enables long circulation times
- be of a size that allows extravasation and accumulation in the tumour tissue.

#### b. First-step targeting agents

Coupling of targeting agents can be performed in a number of ways. Either the targeting agent can be provided with a lipophilic region, which is attached in the phospholipid membrane of the SLT particles, or they can be attached to the outer PEG-part by different chemical methods.

The cell targeting agents are preferably selected from the group of substances that bind to targets consisting of, for example, folate or EGF-receptors which are overexpressed in some types of tumour cancer cells; c-erb-B2 protein which is related to the EGF-receptor and often seems to be abundant in some adenocarcinomas, hematopoietic targets, such as the CD20 or CD32 antigens, which are expressed in some hematopoietic tumour diseases. Tumour specific mutations of receptors and tumour associated antigens, such as CEA, CA59, and CA19-9, are also candidate targets. Thus, several potential targets exist.

The cell targeting agent must have the following properties:

- high and specific affinity for receptors and antigens overexpressed on the target cells
- mediate intracellular deposition of toxic component
- show a stable coupling to the outside of the liposome.

#### c. Second-step targeting agents

Preferred compounds of the invention are stable nuclide- and radionuclide-carrying DNA-intercalators such as phenanthridium, acridine and naphthalimide derivatives, and also compounds which intercalate electrostatically with DNA such as spermine, spermidine, and putrecine derivatives. The intercalators are especially suitable for tumour therapy because both the active substance and the DNA intercalation itself might provide a therapeutic action.

The second step targeting agent must have the following properties:

- high affinity for the nuclear DNA
- high water solubility at physiological pH and ionic strength
- permit efficient loading to fill the lipid carrier
- show minimal leakage when enclosed in the lipid carrier

#### d. Drugs (nuclides)

##### Nuclides for therapy

Short range radiators, which give high local ionization density, e.g.  $^{125}\text{I}$  (Auger radiation) and  $^{211}\text{At}$  ( $\alpha$ -particles) will be applied to obtain maximum effect in a single targeted cell.

The stable nuclide  $^{10}\text{B}$  is another drug candidate according to the invention.  $^{10}\text{B}$  is activated by externally applied neutrons.  $^{157}\text{Gd}$  is another candidate for neutron activation. Other alternatives are stable iodine or bromine which can be activated with photons.

In addition, these can be combined with radionuclides with long range  $\beta$ -radiation, primarily halogens such as  $^{131}\text{I}$ , but also other nuclides such as  $^{32}\text{P}$  and the metals  $^{67}\text{Cu}$ ,  $^{90}\text{Y}$  and  $^{189}\text{Re}$ . These are applied to obtain cross-fire radiation in bigger cell groupings.


##### Nuclides for distribution studies in vivo

Gamma radiators will be incorporated in lipid carriers to allow distribution studies in humans by PET- and SPECT-techniques (Nilsson et al 1995, Westlin et al 1995). For this purpose we also intend to use positron radiators in the halogen group with relatively long half lives such as  $^{76}\text{Br}$  and  $^{124}\text{I}$ , which are suitable for "macromolecular" PET. For SPECT we intend to use halogens such as  $^{131}\text{I}$ . Different types of radioactive metals can also be applied.

### e. Composition of one promising SLT-particle

Unilamellar liposomes with a diameter of 120 nm composed of 55 mol% 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 40 mol% cholesterol (Chol) and 5 mol% 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly(ethylene glycol)-2000] (PEG(2000)-DSPE). The liposomes are prepared by multiple extrusion through polycarbonate filters with pore size 100 nm.

Enclosed in the aqueous interior of the liposomes is the compound 1,8-diamino-4-N-3-[12-(N-9-acridinyl-3-aminopropyl)-*p*-carborane-1-yl] propyl-4-azooctane hydrogen chloride (WSA1) having the following structural formula:



The liposomes are loaded by use of citric acid pH-gradient. Liposomes are prepared in 500 mM citrate buffer with pH 4.0. The external medium is titrated to pH 7.7 with sodium carbonate. WSA is thereafter added and allowed to load for 20 minutes at 60°C. The final formulation contains 40 mg/ml of total lipid and 12 mg/ml of WSA1 which corresponds to about  $1 \times 10^5$  WSA, or  $1 \times 10^6$  B, per liposome.

The formulation is stable in both buffer and serum, less than 15% of the encapsulated WSA 1 is released after 48h incubation at 37°C.

The liposomes have epidermal growth factor (EGF), for targeting against the normal EGF receptor, or a ligand directed against mutated EGF receptor covalently linked to the distal end of the PEG chains. Alternatively, PEG is excluded in the liposome preparation and the ligand is coupled directly to the liposome surface via conjugation to DSPE.

## References

Carlsson, J.; Gedda, L.; Grönvik, C.; Hartman, T.; Lindström, A.; Lindström, P.; Lundquist, H.; Lövquist, A.; Malmquist, J.; Olsson, P.; Essand, M.; Pontén, J.; Sjöberg, S.; and Westermarck, B. 1994. Strategy for boron neutron capture therapy against tumor cells with over-expression of the epidermal growth factor-receptor. *Int. J. Radiation Oncol. Biol. Phys.* 30:105-115.

Gedda, L.; Silvander, M.; Sjöberg, S.; Tjarks, W., and Carlsson, J. 1997. Cytotoxicity and subcellular localization of boronated phenantridinium analogues. *Anti-Cancer Drug Design* 12:671-85.

Kirpotin, D.; Park, J.W.; Hong, K.; Zalipsky, S.; Li, W.; Carter, P.; Benz, C.C., and Papahadjopoulos, D. 1997. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells *in vitro*. *Biochemistry* 36:66-75.

Lasic, D. and Martin, F. (Eds.), 1995. *Stealth Liposomes*. CRC Press, Boca Raton.

Lee, R.J. and Low, P.S. 1994. Delivery of liposomes into cultured KB cells via folate-receptor mediated endocytosis. *J. Biol. Chem.* 4:3198-3204.

Nilsson, S.; Reubi, J.C.; Kälkner, K.M.; Laissue, J.A.; Horisberger, U.; Olerud, C., and Westlin, J.E. 1995. Metastatic hormone-refractory prostatic adenocarcinoma express somostatin receptors and is visualized by 11-In-DTPA-D-Phe-1-octreotide scintigraphy. *Cancer Res.* 55:5805-5810.

Park, J.W., Hong, K., Carter, P., Asgari, H., Guo, L.Y., Keller, G.A., Wirth, C., Shalaby, R., Kotts, C., Wood, W.I., Papahadjopoulos, D., and Benz, C.C. 1995. Development of anti-p185HER2 immunoliposomes for cancer therapy. *Proc. Natl. Acad. Sci. U.S.A.* 92, 1327-1331.

Press, O. W. 1995. Treatment of recurrent lymphomas with unmodified antibodies and radioimmunoconjugates. *Tumor Targeting* 1:31-35.

Sjöberg, S.; Carlsson, J.; Ghaneolhosseini, H.; Gedda, L.; Hartman, T; Malmquist, J.; Naeslund, C.; Olsson, P.; and Tjarks, W. "Chemistry and biology of some low molecular weight boron compounds for Boron Neutron Capture Therapy", *J. Neuro-Oncol.* 1997, 33, 41-52.

Sjöberg, S. "Boron Chemistry for NCT".." In; Larsson, B.; Crawford, J. and Weinreich (eds.) *Advances in NCT Vol. 2: Chemistry and Biology. Elsevier Scientific*, Amsterdam 1997, pp 3-21.

Westlin, J.E.; Edgren, M.; Letocha, H.; Stridsberg, M.; Wilander, E., and Nilsson, S. Positron emission tomography utilizing 11-C-5-hydroxytryptophan, plasma biochemistry and neuroendocrine immunohistochemistry of metastatic renal cell carcinoma. *Oncology Reports* 2:543-548.

Ghaneolhosseini H., Tjarks W., and Sjöberg S. Synthesis of Boronated Phenanthridinium Derivatives for potential Use in Boron Neutron Capture Therapy (BNCT). *Tetrahedron* 1997, 53, 17519-17526.

**CLAIMS**

1. A drug delivery system with two-step targeting, **characterized in** that it comprises:
  - a) a lipid carrier provided with cell targeting agent(s) to target the drug delivery system to specific cells or tissue; and
  - b) drug(s) enclosed in said lipid carrier and provided with a DNA targeting agent to target the drug to the nucleus of specific target cells.
2. A drug delivery system according to claim 1, **characterized in** that the ratio between a) and b) is between 1 and  $10^{-8}$ .
3. A drug delivery system according to claim 1 or 2, **characterized in** that the cell targeting agent is selected from the group consisting of natural or synthetic ligands, antibodies and antibody fragments.
4. A drug delivery system according to claims 1, 2 or 3, **characterized in** that the drugs are stable nuclides suitable for activation.
5. A drug delivery system according to claims 1, 2 or 3, **characterized in** that the drugs are radioactive.
6. A drug delivery system according to any one of the claims 1-5, **characterized in** that the DNA targeting agent is a DNA intercalator or an agent that interacts electrostatically or reacts chemically with DNA.
7. A drug delivery system according to any one of the claims 1-6, **characterized in** that it comprises:
  - a) as a lipid carrier, unilamellar liposomes with a diameter of 120 nm composed of 55 mol% 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 40 mol% cholesterol (Chol) and 5 mol% 1,2-distearoyl-sn-glycero-3-

phosphoethanolamine-N-[poly(ethylene glycol)-2000] (PEG(2000)-DSPE); and as a cell targeting agent, epidermal growth factor (EGF), or a substance binding to the mutated EGF receptor, covalently linked to the distal end of the PEG chains; and, as DNA targeted drug,

b) the compound 1,8-diamino-4-N-3-[12-(N-9-acridinyl-3-aminopropyl)-*p*-carborane-1-yl] propyl-4-azooctane hydrogen chloride (WSA1).

8. A method for cancer therapy, comprising administering to a subject in need thereof a therapeutically efficient amount of the drug delivery system according to claim 4 and subsequently irradiating the cancer area.
9. A method for cancer therapy and/or diagnostics, comprising administering to a subject in need thereof a therapeutically and/or diagnostically efficient amount of the drug delivery system according to claim 5.

# AMENDED CLAIMS

[received by the International Bureau on 29 April 1999 (29.04.99);  
original claims 1,4-9 replaced by new claims 1,4-7 remaining claims unchanged (2 pages)]

1. A drug delivery system with two-step targeting, **characterized in** that it comprises:
  - a) a lipid carrier provided with cell targeting agent(s) to target the drug delivery system to specific cells or tissue; and
  - b) drug(s) enclosed in said lipid carrier and provided with a DNA targeting agent to target the drug to the nucleus of specific target cells, wherein the drugs are radioactive nuclides or stable nuclides suitable for activation.
2. A drug delivery system according to claim 1, **characterized in** that the ratio between a) and b) is between 1 and  $10^{-8}$ .
3. A drug delivery system according to claim 1 or 2, **characterized in** that the cell targeting agent is selected from the group consisting of natural or synthetic ligands, antibodies and antibody fragments.
4. A drug delivery system according to any one of the claims 1-3, **characterized in** that the DNA targeting agent is a DNA intercalator or an agent that interacts electrostatically or reacts chemically with DNA.
5. A drug delivery system according to any one of the claims 1-4, **characterized in** that it comprises:
  - a) as a lipid carrier, unilamellar liposomes with a diameter of 120 nm composed of 55 mol% 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 40 mol% cholesterol (Chol) and 5 mol% 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly(ethylene glycol)-2000] (PEG(2000)-DSPE); and as a cell targeting agent, epidermal growth factor (EGF), or a substance binding to the mutated EGF receptor, covalently linked to the distal end of the PEG chains; and, as DNA targeted drug,



b) the compound 1,8-diamino-4-N-3-[12-(N-9-acridinyl-3-aminopropyl)-*p*-carborane-1-yl] propyl-4-azooctane hydrogen chloride (WSA1).

6. A method for cancer therapy, comprising administering to a subject in need thereof a therapeutically efficient amount of the drug delivery system according to claim 1 in which the drugs are nuclides suitable for activation, and subsequently irradiating the cancer area.
7. A method for cancer therapy and/or diagnostics, comprising administering to a subject in need thereof a therapeutically and/or diagnostically efficient amount of the drug delivery system according to claim 1 in which the drugs are radioactive.

FIG. 1





FIG. 2



## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 9/127, A61K 47/48, A61K 39/44, A61K 51/12  
According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EMBASE, CAPLUS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9741834 A1 (NIKA HEALTH PRODUCTS LIMITED), 13 November 1997 (13.11.97), page 7, line 2 - page 8, line 4, claims 5-6,32-33 --	1-9
X	Pharmaceutical Research, Volume 13, No 3, 1996, Samir C. Mehta et al, "Targeted Drug Delivery for Boron Neutron Capture Therapy" --	1-9
A	WO 9614877 A1 (THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE), 23 May 1996 (23.05.96), page 21, line 3 - line 10; page 28, line 1 - page 19, line 19 --	1-9

☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

- \* Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
  - "E" earlier document but published on or after the international filing date
  - "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  - "O" document referring to an oral disclosure; use, exhibition or other means
  - "P" document published prior to the international filing date but later than the priority date claimed
  - "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  - "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  - "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  - "&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
30 March 1999	12 -04- 1999
Name and mailing address of the ISA: Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. + 46 8 666 02 86	Authorized officer  Anneli Jönsson Telephone No. + 46 8 782 25 00

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5620689 A (THERESA M. ALLEN ET AL), 15 April 1997 (15.04.97), column 6, line 11 - column 8, line 12; column 10, line 54 - column 12, line 16, claims  -- -----	1-9

**Box I** Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8-9  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Remark: Claims 8-9 are directed to methods of treatment of the human or animal body by therapy methods practised on the human or animal body/Rule 39.1(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compositions.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II** Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

02/03/99

International application No.  
PCT/SE 98/02231

Patent document cited in search report			Publication date	Patent family member(s)			Publication date
WO	9741834	A1	13/11/97	AU	2776697 A		26/11/97
				HR	970234 A		30/06/98
-----							
WO	9614877	A1	23/05/96	AU	4407196 A		06/06/96
				BR	9509674 A		16/09/97
				CA	2205414 A		23/05/96
				CN	1171743 A		28/01/98
				EP	0792168 A		03/09/97
				FI	972066 A		14/07/97
				JP	10510145 T		06/10/98
				NO	972228 A		14/07/97
				US	5756668 A		26/05/98
				US	5846712 A		08/12/98
-----							
US	5620689	A	15/04/97	AU	6527294 A		24/10/94
				US	5527528 A		18/06/96
				WO	9422429 A		13/10/94
				US	5213804 A		25/05/93
				US	5356633 A		18/10/94
				US	5843473 A		01/12/98
				AT	115401 T		15/12/94
				AT	122229 T		15/05/95
				AU	642679 B		28/10/93
				AU	654120 B		27/10/94
				AU	6637490 A		16/05/91
				AU	6898291 A		16/05/91
				CA	2067133 A,C		21/04/91
				CA	2067178 A,C		21/04/91
				DE	69015207 D,T		04/05/95
				DE	69019366 D,T		05/10/95
				DK	496835 T		17/07/95
				EP	0496813 A,B		05/08/92
				EP	0496835 A,B		05/08/92
				SE	0496835 T3		
				ES	2071976 T		01/07/95
				FI	921763 A		21/04/92
				FI	921764 A		21/04/92
				GR	3017060 T		30/11/95
				HK	14097 A		14/02/97
				IL	96069 A		08/12/95
				IL	96070 A		30/03/95
				JP	2667051 B		22/10/97
				JP	5501264 T		11/03/93
				JP	5505173 T		05/08/93
				JP	10001431 A		06/01/98
				KR	134982 B		22/04/98
				LU	88854 A		11/03/97
				US	5013556 A		07/05/91
				US	5225212 A		06/07/93
				WO	9105545 A		02/05/91
				WO	9105546 A		02/05/91
-----							